CN113633771A - 氨基酸修饰氨基四苯基卟啉化合物预防治疗纤维化的用途 - Google Patents
氨基酸修饰氨基四苯基卟啉化合物预防治疗纤维化的用途 Download PDFInfo
- Publication number
- CN113633771A CN113633771A CN202111058171.6A CN202111058171A CN113633771A CN 113633771 A CN113633771 A CN 113633771A CN 202111058171 A CN202111058171 A CN 202111058171A CN 113633771 A CN113633771 A CN 113633771A
- Authority
- CN
- China
- Prior art keywords
- fibrosis
- amino acid
- intestinal
- modified amino
- acid modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 amino acid modified amino tetraphenyl porphyrin compound Chemical class 0.000 title claims abstract description 51
- 206010016654 Fibrosis Diseases 0.000 title abstract description 19
- 230000004761 fibrosis Effects 0.000 title abstract description 19
- 206010072877 Intestinal fibrosis Diseases 0.000 claims abstract description 48
- 238000002428 photodynamic therapy Methods 0.000 claims abstract description 39
- 208000005069 pulmonary fibrosis Diseases 0.000 claims abstract description 23
- 239000003814 drug Substances 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 8
- 238000001727 in vivo Methods 0.000 claims description 5
- 210000001072 colon Anatomy 0.000 abstract description 42
- 229920003045 dextran sodium sulfate Polymers 0.000 abstract description 39
- 230000007705 epithelial mesenchymal transition Effects 0.000 abstract description 11
- 210000004072 lung Anatomy 0.000 abstract description 11
- 102000008186 Collagen Human genes 0.000 abstract description 10
- 108010035532 Collagen Proteins 0.000 abstract description 10
- 229920001436 collagen Polymers 0.000 abstract description 10
- 230000008021 deposition Effects 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 5
- VVTSZOCINPYFDP-UHFFFAOYSA-N [O].[Ar] Chemical compound [O].[Ar] VVTSZOCINPYFDP-UHFFFAOYSA-N 0.000 abstract description 3
- 238000005261 decarburization Methods 0.000 abstract description 3
- 230000028327 secretion Effects 0.000 abstract description 3
- 230000008951 colonic inflammation Effects 0.000 abstract description 2
- 239000002253 acid Substances 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 24
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 241000700159 Rattus Species 0.000 description 14
- 230000000968 intestinal effect Effects 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 12
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 12
- 239000007920 enema Substances 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 241000792859 Enema Species 0.000 description 9
- 229940095399 enema Drugs 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 108010006654 Bleomycin Proteins 0.000 description 8
- 229960001561 bleomycin Drugs 0.000 description 8
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 6
- 238000007619 statistical method Methods 0.000 description 6
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 238000003304 gavage Methods 0.000 description 5
- 210000004969 inflammatory cell Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 101710188689 Small, acid-soluble spore protein 1 Proteins 0.000 description 4
- 101710188693 Small, acid-soluble spore protein 2 Proteins 0.000 description 4
- 101710166422 Small, acid-soluble spore protein A Proteins 0.000 description 4
- 101710166404 Small, acid-soluble spore protein C Proteins 0.000 description 4
- 101710174019 Small, acid-soluble spore protein C1 Proteins 0.000 description 4
- 101710174017 Small, acid-soluble spore protein C2 Proteins 0.000 description 4
- 101710174574 Small, acid-soluble spore protein gamma-type Proteins 0.000 description 4
- 102100036407 Thioredoxin Human genes 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 4
- 238000001764 infiltration Methods 0.000 description 4
- 230000003870 intestinal permeability Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 102000013127 Vimentin Human genes 0.000 description 3
- 108010065472 Vimentin Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 230000003176 fibrotic effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000007489 histopathology method Methods 0.000 description 3
- 238000001543 one-way ANOVA Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000003504 photosensitizing agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 210000004953 colonic tissue Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 235000020828 fasting Nutrition 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000012160 loading buffer Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 235000020926 24-h fasting Nutrition 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- 102000016893 Amine Oxidase (Copper-Containing) Human genes 0.000 description 1
- 108010028700 Amine Oxidase (Copper-Containing) Proteins 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010022699 Intestinal stenosis Diseases 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FBVSXKMMQOZUNU-NSHDSACASA-N N2,N6-Bis{[(2-methyl-2-propanyl)oxy]carbonyl}lysine Chemical compound CC(C)(C)OC(=O)NCCCC[C@@H](C(O)=O)NC(=O)OC(C)(C)C FBVSXKMMQOZUNU-NSHDSACASA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- UATJOMSPNYCXIX-UHFFFAOYSA-N Trinitrobenzene Chemical compound [O-][N+](=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 UATJOMSPNYCXIX-UHFFFAOYSA-N 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000009693 chronic damage Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 210000005026 intestinal epithelial barrier Anatomy 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 206010022694 intestinal perforation Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008807 pathological lesion Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000004879 pulmonary tissue Anatomy 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940063675 spermine Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
技术领域
本发明属于药物领域,具体涉及氨基酸修饰氨基四苯基卟啉化合物预防和治疗肠纤维化和肺纤维化的用途,特别是涉及四个赖氨酸修饰的氨基四苯基卟啉化合物在制备抗肠纤维化和抗肺纤维化药物中的应用。
背景技术
肠纤维化是肠道慢性炎症和损伤活动过度的、不可逆的损伤愈合反应。大量慢性炎性细胞的反复浸润会导致细胞外基质(extracellular matrix,ECM)异常聚集、间质细胞大量增殖,从而形成肠纤维化[1,2]。肠纤维化是炎症性肠病常见的并发症,且其在克罗恩病中的患病率明显高于溃疡性结肠炎。肠壁纤维化导致肠道变形缩短,肠腔狭窄,甚至引起肠梗阻和穿孔[3]。目前常用的临床药物如皮质类固醇、氨基水杨酸、免疫抑制剂以及生物制剂抗肿瘤坏死因子抗体,虽然可以改善肠道炎症,但疗效欠佳,导致手术切除术成为严重症状性肠纤维化的唯一选择。因此,防治甚至逆转肠纤维化已成为临床IBD治疗中亟待解决的重要问题。
肺纤维化是一种由诸多原因引起的以肺泡结构严重破坏,弥散性肺泡炎症及肺间质纤维化为特点的疾病。随着工业化的不断发展,肺纤维化发病人数逐年增加,但是由于缺乏有效的治疗手段,患者的预后差,死亡率高,严重影响人类健康。
肠道间质细胞是参与肠纤维化发生的关键细胞,是产生ECM的主要细胞,包括肠成纤维细胞、肠肌成纤维细胞和平滑肌细胞等,活化的肠成纤维细胞主要来源于组织中间质细胞、上皮或内皮转化的间质细胞[4-6]。近年来研究表明,上皮间质转化(epithelial-mesenchymal transition,EMT)是肠成纤维细胞来源的一条重要途径[7,8]。EMT是组织形成、癌症发生以及器官纤维化的关键中间过程,其特征在某些病理、生理及环境等因素作用下,上皮细胞失去细胞极性及细胞间连接,且上皮细胞标志物如E细胞钙黏蛋白、细胞角蛋白等逐渐消失,而间质细胞标志物如成纤维细胞特异蛋白、平滑肌激动蛋白等逐渐增多的过程。
有多项研究表明,EMT促进肠道纤维化[9-12]。含铜胺氧化酶1(Amine oxidasecopper-containing 1,AOC1)是一种含铜的胺氧化酶,催化丙胺和精胺等化合物的降解。同时,有报道表明下调AOC1可抑制上皮-间充质转化EMT的过程[13]。
光动力疗法(Photodynamic Therapy,PDT)是当前国际上正在发展的一种新技术,它是利用光敏剂的光动力反应,选择性的作用于靶组织,并产生组织效应的治疗方法[14]。其优点为毒副作用性小,治疗时间短,靶向性强,在治疗的同时不危及正常组织。随着各种内窥镜和纤维光学技术的飞速发展,利用光动力疗法治疗内腔疾病逐渐成为可能。有研究显示PDT可以治疗炎症性肠病[13],而是否可以改善肠纤维化程度还需要进一步研究。
本实验室设计合成了具有良好理化性质的氨基酸修饰氨基四苯基卟啉化合物LD4,研究表明该化合物可以促进结肠粘膜愈合,调节肠道菌群,改善溃疡性结肠炎的临床症状,同时降低AOC1介导的粘膜炎症反应。基于上述结果,我们将该光敏剂用于肠纤维化和肺纤维化的PDT预防和治疗。结果发现LD4-PDT可以降低Collagen-Ⅰ、Collagen-Ⅲ和α-SMA蛋白表达,通过下调AOC1抑制EMT的过程,进而减轻炎症反应及胶原沉积,改善肠纤维化程度。同时,也发现LD4-PDT可改善肺纤维化程度。我们的研究显示LD4干预肠纤维化和肺纤维化可能是通过AOC1发挥作用并有望开发出一种新型的高效低毒预防和治疗纤维化的光敏剂。
参考文献
[1]范燕云,王承党.炎症性肠病肠壁纤维化机制研究进展[J].医学综述,2010,16(18):2760-2764.
[2]吕春华,李弼民.炎症性肠病纤维化的研究进展[J].实用临床医学,2009,10(2):127-129.
[3]Lin X X,Qiu Y,Zhuang X J,et al.Intestinal stricture in Crohn'sdisease:A 2020 update[J].J Dig Dis,2021,22(7):390-398.
[4]Chen W,Chen Y W,Su J,et al.CaMKII mediates TGFβ1-inducedfibroblasts activation and its cross talk with colon cancer cells[J].Dig DisSci,2021.
[5]Liu J,Deng T,Wang Y X,et al.Calycosin inhibits intestinal fibrosison CCD-18Co cells via modulating transforming growth factor-β/Smad signalingpathway[J].Pharmacology,2019,104(1-2):81-89.
[6]Amamou A,Rouland M,Yaker L,et al.Dietary salt exacerbatesintestinal fibrosis in chronic TNBS colitis via fibroblasts activation[J].SciRep,2021,11(1):15055.
[7]Jia W X,Yang M Y,Han F,et al.Effect and mechanism of TL1Aexpression on epithelial-mesenchymal transition during chronic colitis-related intestinal fibrosis[J].Mediators Inflamm,2021:5927064.
[8]潘宜久,孟立娜.上皮间质转化与炎症性肠病肠道纤维化研究进展[J].浙江医学,2019,41(21):2332-2334.
[9]Yu M L,Wu H,Wang J H,et al.Vitamin D receptor inhibits EMT viaregulation of the epithelial mitochondrial function in intestinal fibrosis[J].J Biol Chem,2021.296:100531.
[10]Jun Y K,Kwon S H,Yoon H T,et al.Toll-like receptor 4regulatesintestinal fibrosis via cytokine expression and epithelial-mesenchymaltransition[J].Sci Rep,2020,10(1):19867.
[11]Ortiz-Masiá D,Gisbert-Ferrándiz L,Bauset C,et al.Succinateactivates EMT in intestinal epithelial cells through SUCNR1:a novelprotagonist in fistula development[J].Cells,2020,9(5):1104.
[12]Di Gregorio J,Sferra R,Speca S,et al.Role of glycogen synthasekinase-3βand PPAR-γon epithelial-to-mesenchymal transition in DSS-inducedcolorectal fibrosis[J].PLoS One,2017,12(2):e0171093.
[13]Xu F,Xu Y,Xiong J H,et al.AOC1 contributes to tumor progressionby promoting the AKT and EMT pathways in gastric cancer[J].Cancer Manag Res,2020,12:1789-1798.
[14]Baldea I,Filip A G.Photodynamic therapy in melanoma--an update[J].J Physiol Pharmacol,2012,63(2):109-118.
发明内容
本发明的目的在于克服现有技术的不足,提供氨基酸修饰氨基四苯基卟啉化合物作为预防和治疗肠纤维化药物的用途。
本发明的第二个目的是提供氨基酸修饰氨基四苯基卟啉化合物作为预防和治疗肺纤维化药物的用途。
本发明的目的主要通过以下技术方案实现:
氨基酸修饰氨基四苯基卟啉化合物在制备预防和治疗肠纤维化药物的应用,所述的氨基酸修饰氨基四苯基卟啉化合物具有下述结构:
所述的药物为光动力治疗药物。
氨基酸修饰氨基四苯基卟啉化合物在制备预防和治疗肺纤维化药物的应用,所述的氨基酸修饰氨基四苯基卟啉化合物具有下述结构:
所述的药物为光动力治疗药物。
实验证明:氨基酸修饰氨基四苯基卟啉化合物在光动力治疗葡聚糖硫酸钠和三硝基苯磺酸构建的大、小鼠肠纤维化模型中,可以明显减轻结肠炎症及纤维化程度,抑制结肠组织中胶原的分泌和沉积,同时通过抑制AOC1的表达来抑制上皮间充质转化程度,从而预防和治疗肠纤维化。氨基酸修饰氨基四苯基卟啉化合物在光动力治疗博来霉素构建的小鼠肺纤维化模型中,可以明显减轻肺组织炎症及纤维化程度,从而预防和治疗肺纤维化。
附图说明
图1为本发明实施例1的氨基酸修饰氨基四苯基卟啉化合物对葡聚糖硫酸钠建立的小鼠肠纤维化模型平均体重的影响。
图2为本发明实施例1的氨基酸修饰氨基四苯基卟啉化合物对葡聚糖硫酸钠建立的小鼠肠纤维化模型结肠长度的影响。
图3为本发明实施例1的氨基酸修饰氨基四苯基卟啉化合物对葡聚糖硫酸钠建立的小鼠肠纤维化模型结肠通透性的影响。
图4为本发明实施例1的氨基酸修饰氨基四苯基卟啉化合物对葡聚糖硫酸钠建立的小鼠肠纤维化模型结肠组织HE染色图(×100)。
图5为本发明实施例1的氨基酸修饰氨基四苯基卟啉化合物对葡聚糖硫酸钠建立的小鼠肠纤维化模型结肠组织Masson染色图(×100)。
图6为本发明实施例1的氨基酸修饰氨基四苯基卟啉化合物对葡聚糖硫酸钠建立的小鼠肠纤维化模型结肠组织中Collagen-Ⅰ、Collagen-Ⅲ和α-SMA蛋白表达水平的影响。
图7为本发明实施例1的氨基酸修饰氨基四苯基卟啉化合物对葡聚糖硫酸钠建立的小鼠肠纤维化模型结肠组织中TNF-α和IL-6蛋白表达水平的影响。
图8为本发明实施例1的氨基酸修饰氨基四苯基卟啉化合物对葡聚糖硫酸钠建立的小鼠肠纤维化模型结肠组织中AOC1、E-cadherin和Vimentin蛋白表达水平的影响。
图9为本发明实施例1的氨基酸修饰氨基四苯基卟啉化合物对三硝基苯磺酸建立的大鼠肠纤维化模型结肠组织HE染色图(×100)。
图10为本发明实施例1的氨基酸修饰氨基四苯基卟啉化合物对三硝基苯磺酸建立的大鼠肠纤维化模型结肠组织Masson染色图(×100)。
图11为本发明实施例1的氨基酸修饰氨基四苯基卟啉化合物对三硝基苯磺酸建立的大鼠肠纤维化模型结肠组织中Collagen-Ⅰ、Collagen-Ⅲ和α-SMA蛋白表达水平的影响。
图12为本发明实施例1的氨基酸修饰氨基四苯基卟啉化合物对博莱霉素建立的小鼠肺纤维化模型肺组织HE染色图(×200)。
图13为本发明实施例1的氨基酸修饰氨基四苯基卟啉化合物对博莱霉素建立的小鼠肺纤维化模型肺组织Masson染色图(×200)。
具体实施方式
下面通过实施例对本发明作进一步说明,其目的仅在于更好的理解本发明的内容而非限制本发明的保护范围:
实施例1氨基酸修饰氨基四苯基卟啉化合物(LD4)的合成
将Boc-Lys(Boc)-OH(467.67mg,1.35mmol)置于反应瓶中,N2保护下加入干燥的THF 20ml,磁子搅拌。冷却至-17℃,加入三乙胺(197.60μl,1.42mmol)和氯甲酸乙酯(131.10μl,1.38mmol)反应1h,生成白色沉淀,过滤,弃去沉淀。取四氨基卟啉(202.40mg,0.30mmol)溶解于15ml THF中,将上述滤液加入,室温搅拌反应14h。TLC(二氯甲烷:甲醇:氨水=60:1:0.6)监测反应进程。反应完全后,将反应液倒入冰水中,析出沉淀,过滤,水洗3次,得到紫色固体。最后柱层析分离(洗脱剂:二氯甲烷:甲醇:氨水=30:1:0.4)得产物596.13mg,产率93%。
将上述步骤得到的100.00mg样品用10ml干燥的CH2Cl2溶解,缓慢滴加三氟乙酸10ml,室温反应30min。旋除溶剂,加入无水乙醚,生成浅绿色沉淀,过滤,30ml二氯甲烷和30ml无水乙醚各洗涤3次。再用20ml蒸馏水将绿色沉淀溶解,氨水调节PH 7-8,析出紫色沉淀,过滤,水洗2次,柱层析分离得到氨基酸修饰氨基四苯基卟啉化合物LD4 51.96mg,产率87%。
实施例2氨基酸修饰氨基四苯基卟啉化合物(LD4)预防和治疗肠纤维化
本发明实施例1制备的氨基酸修饰氨基四苯基卟啉化合物LD4治疗葡聚糖硫酸钠(DSS)诱导的小鼠肠纤维化的在体实验过程,包括如下步骤:
C57BL/6J小鼠正常组饮用纯净水,其余各组采用1.5%DSS水饮用一周,纯净水恢复两周,接着2%DSS水饮用一周恢复两周,再循环一次2%DSS水饮用一周来建立肠纤维化模型。将小鼠随机分为6组,每组10只,处理方法如下:1.Control组(生理盐水);2.DSS组(DSS饮水);3.LD4-PDTL组(DSS饮水和低剂量LD4 60μg/kg灌肠);4.LD4-PDTM组(DSS饮水和中剂量LD4 120μg/kg灌肠);5.LD4-PDTH组(DSS饮水和高剂量LD4 240μg/kg灌肠);6.柳氮磺胺吡啶(SASP)组(DSS饮水和阳性对照药物SASP 500mg/kg灌胃)。建立肠纤维化模型后,第9周开始治疗。LD4每隔1天灌肠一次,同时灌胃SASP,共4次。每次LD4灌肠后30min,结肠用密集的650nm PDT系统照射,能量密度为25J/cm2。每日测量体重和摄食量。第11周,禁食24小时后处死所有小鼠,取全结肠和血,解剖并保存在-80℃,部分组织用4%多聚甲醛固定。
血清中FITC-dextran荧光强度检测动物肠道的通透性可以通过使用荧光示踪剂检测血清中的荧光强度进行半定量检测。取正常收集无溶血血清,称取FITC-dextran粉末200μg,溶于5ml血清中,倍比稀释10次,再使用酶标仪检测荧光强度,即可得到标准曲线。LD4-PDT治疗后,处死动物当天,提前4h禁食。灌胃配制好的FITC-dextran示踪剂,剂量0.6mg/g体重。动物处死前取血,收集无溶血血清。将血清加入96孔板中,每孔100μl,使用酶标仪检测荧光强度(激发光488nm,发射光520nm),通过标准曲线公式可计算出动物血清中FITC-dextran的含量。
标本获取分析取出固定在4%的多聚甲醛的结肠组织,脱水、包埋、切片(厚度为5μm),进行HE染色和Masson染色,每组切片染色完成后进行炎症程度和纤维化组织病理学分析。
蛋白免疫印迹组织使用RIPA裂解液4℃ 30min裂解,12000rpm,4℃离心20min。使用BCA法进行蛋白定量。根据体积取适量样品加入4×loading buffer后,100℃煮沸变性10min。蛋白用12%SDS-PAGE预制胶分离,然后转移到PVDF膜上。膜用5%脱脂牛奶封闭,TBST稀释一抗,抗体浓度根据说明书配置。
统计学分析采用SPSS 18.0和GraphPad Prism 6进行数据分析。所有数据以均数±标准差表示。采用单因素方差分析进行统计学分析,当P<0.05认为有统计学意义。
LD4-PDT对DSS诱导的小鼠肠纤维化模型体重和结肠长度的影响结果表明,正常对照组小鼠体重稳步上升;与对照组相比,DSS组小鼠体重有所下降;与DSS相比,LD4-PDT增加了小鼠的体重(图1)。肉眼观察取出的动物结肠组织,可发现正常对照组的小鼠结肠内壁完整,皱襞规整,血管纹理清晰,无明显的糜烂、溃疡或肉芽肿。DSS组可见结肠缩短,黏膜显著充血水肿,散在性糜烂或溃疡伴出血及溃疡。其他给药组动物的结肠也可见不同程度的病理损伤,但是结肠的长度和肠壁变薄情况均有不同程度改善。此外,LD4-PDT小鼠结肠长度明显长于DSS小鼠结肠(图2)。因此,LD4-PDT增加DSS诱导的小鼠体重和结肠长度。
LD4-PDT对DSS诱导的小鼠肠纤维化模型肠道通透性的影响炎症性肠病的动物肠道上皮和肠道黏膜都会有不同程度的损伤,而肠道上皮屏障是肠道固有免疫的重要组成部分,通过测定肠壁通透性来确定疾病的活动性。我们通过灌胃实验动物异硫氰酸荧光素标记的葡聚糖(FITC-dextran),检测其血清中荧光强度可以间接反映动物肠道的通透性。数据显示,正常对照组小鼠血清中FITC含量很低,说明肠道通透性正常。DSS组的FITC含量明显升高说明肠道通透性增加,肠壁有损伤,而LD4-PDT和SASP各组的FITC含量均有显著降低,说明药物对保护肠道有一定的作用(图3)。
LD4-PDT对DSS诱导的小鼠肠纤维化模型炎症程度和纤维化程度的影响HE染色病理学分析显示,DSS组上皮细胞脱落,膜下层炎性细胞浸润,溃疡形成,粘膜腺体排列紊乱、破坏、消失,杯状细胞减少甚至消失,发生大量的炎性细胞浸润。与DSS组相比,LD4-PDT处理可使小鼠结肠病理症状明显减轻(图4)。小鼠结肠组织Masson染色病理学分析显示,DSS组小鼠结肠组织细胞外基质明显增生,有大量染蓝的胶原纤维增生沉积,形成广泛的纤维化;而LD4-PDT各治疗组与DSS组相比显著减轻结肠组织胶原纤维沉积(图5)。与DSS组相比,用药各剂量组小鼠结肠组织中Collagen-Ⅰ、Collagen-Ⅲ和α-SMA蛋白表达显著性降低(图6)。结果表明LD4-PDT可以减少DSS诱导肠纤维化的小鼠结肠组织胶原纤维生成,抑制胶原沉积减轻肠纤维化。进一步检测结肠组织中IL-6和TNF-α表达。结果显示,与DSS组相比,LD4-PDT治疗后的小鼠结肠组织中IL-6和TNF-α含量较低(图7)。
LD4-PDT对AOC1/EMT通路影响检测小鼠结肠组织中AOC1、E-cadherin和Vimentin蛋白表达水平。结果显示,与DSS组相比,LD4-PDT各剂量组小鼠结肠组织中AOC1和Vimentin蛋白表达显著性降低,E-cadherin蛋白表达显著升高(图8)。
实施例3氨基酸修饰氨基四苯基卟啉化合物(LD4)预防和治疗肠纤维化
本发明实施例1制备的氨基酸修饰氨基四苯基卟啉化合物LD4治疗三硝基苯磺酸(TNBS)诱导的大鼠肠纤维化的在体实验过程,包括如下步骤:
大鼠在模型诱导前禁食24h,使用10%水合氯醛麻醉。使用150mg/kg的TNBS,直径3mm聚乙烯橡胶导管(插入近端肛门直肠8cm)注射大鼠结肠内,建立肠纤维化模型。将大鼠随机分为6组,每组6只,处理方法如下:1.Control组(生理盐水);2.TNBS组(TNBS灌肠);3.LD4-PDTL组(TNBS和低剂量LD4,60μg/kg,均灌肠);4.LD4-PDTM组(TNBS和中剂量LD4,120μg/kg,均灌肠);5.LD4-PDTH组(TNBS和高剂量LD4 240μg/kg,均灌肠);6、SASP组(TNBS灌肠及阳性对照药物,SASP 500mg/kg,灌胃)。以TNBS灌肠当日为第0天,第7天开始治疗。LD4每隔1天灌肠一次,同时灌胃SASP,共4次。每次治疗后30min,结肠部位用密集的650nm PDT系统照射,能量密度为25J/cm2。治疗结束,第19日禁食24h后处死所有大鼠,取全结肠和血,解剖并保存在-80℃,部分组织用4%多聚甲醛固定。
标本获取分析取出固定在4%的多聚甲醛的结肠组织,脱水、包埋、切片(厚度为5μm),进行HE染色和Masson染色,每组切片染色完成后进行炎症程度和纤维化组织病理学分析。
蛋白免疫印迹组织使用RIPA裂解液4℃ 30min裂解,12000rpm,4℃离心20min。使用BCA法进行蛋白定量。根据体积取适量样品加入4×loading buffer后,100℃煮沸变性10min。蛋白用12%SDS-PAGE预制胶分离,然后转移到PVDF膜上。膜用5%脱脂牛奶封闭,TBST稀释一抗,抗体浓度根据说明书配置。
统计学分析采用SPSS 18.0和GraphPad Prism 6进行数据分析。所有数据以均数±标准差表示。采用单因素方差分析进行统计学分析,当P<0.05认为有统计学意义。蛋白组学采用t-test进行差异分析,p≤0.05,Fold change≥1.5倍,定义为差异蛋白。
LD4-PDT对TNBS诱导的大鼠肠纤维化模型炎症程度和纤维化程度的影响HE染色病理分析显示,DSS组中存在大量的炎性细胞浸润。与TNBS组相比,LD4-PDT处理可使大鼠结肠炎症程度明显减轻(图9)。大鼠结肠组织Masson染色病理学分析显示,TNBS组中大鼠结肠组织胶原纤维增生沉积显著增加;而LD4-PDT各治疗组与TNBS组相比结肠组织胶原纤维沉积显著减轻(图10)。同样与TNBS组相比,用药各剂量组中大鼠结肠组织中Collagen-Ⅰ、Collagen-Ⅲ和α-SMA蛋白表达显著性降低(图11)。因此,结果表明LD4-PDT可以减轻TNBS诱导的肠纤维化。
实施例4氨基酸修饰氨基四苯基卟啉化合物(LD4)预防和治疗肺纤维化
本发明实施例1制备的氨基酸修饰氨基四苯基卟啉化合物LD4治疗博来霉素诱导的小鼠肺纤维化的在体实验过程,包括如下步骤:
15只ICR雄性小鼠随机分为对照组(Control),模型组(BLM),LD4-PDT组(240μg/kg,气管滴注),每组5只。对照组气管内滴入0.9%氯化钠注射液,其余各组小鼠经气管给予博来霉素(BLM)溶液5mg/kg,建立肺纤维化模型。造模后第二天开始,LD4(240μg/kg,100μl)每周气管滴注一次,滴注药物30min后,在4、5肋骨之间进针于右肺中叶处用650nm PDT系统照射,能量密度为25J/cm2。连续三周,第22日禁食24h后处死所有小鼠,肺组织用4%多聚甲醛固定。
标本获取分析取出固定在4%的多聚甲醛的结肠组织,脱水、包埋、切片(厚度为5μm),进行HE染色和Masson染色,每组切片染色完成后进行炎症程度和纤维化组织病理学分析。
统计学分析采用SPSS 18.0和GraphPad Prism 6进行数据分析。所有数据以均数±标准差表示。采用单因素方差分析进行统计学分析,当P<0.05认为有统计学意义。
HE染色图和Masson染色图显示对照组小鼠的肺组织结构清晰,肺泡完整,肺间隔未见明显增厚、水肿、炎症及纤维化表现;模型组小鼠的肺组织肺泡结构完全破坏消失,炎性细胞浸润,胶原沉积明显增加;LD4-PDT组小鼠的肺组织炎性细胞浸润区域较模型组明显减少,肺组织结构较模型组明显完整,肺泡炎程度及纤维化程度较模型组呈现不同程度的降低(图12和图13)。
综上所述,LD4在光动力治疗葡聚糖硫酸钠和三硝基苯磺酸构建的肠纤维化模型动物时,可以明显减轻结肠炎症及纤维化程度,可抑制结肠组织中胶原的分泌和沉积,同时通过抑制AOC1的表达来进一步抑制上皮间充质转化程度,从而预防和治疗肠纤维化。LD4在光动力治疗博来霉素构建的小鼠肺纤维化模型时,可以明显减轻肺组织炎症及纤维化程度,从而预防和治疗肺纤维化。
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111058171.6A CN113633771B (zh) | 2021-09-09 | 2021-09-09 | 氨基酸修饰氨基四苯基卟啉化合物预防治疗纤维化的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111058171.6A CN113633771B (zh) | 2021-09-09 | 2021-09-09 | 氨基酸修饰氨基四苯基卟啉化合物预防治疗纤维化的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113633771A true CN113633771A (zh) | 2021-11-12 |
CN113633771B CN113633771B (zh) | 2024-05-17 |
Family
ID=78425508
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111058171.6A Active CN113633771B (zh) | 2021-09-09 | 2021-09-09 | 氨基酸修饰氨基四苯基卟啉化合物预防治疗纤维化的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113633771B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5913884A (en) * | 1996-09-19 | 1999-06-22 | The General Hospital Corporation | Inhibition of fibrosis by photodynamic therapy |
US20100087534A1 (en) * | 2005-07-05 | 2010-04-08 | Maria-Anna Ortner | Use of a Photosensitizing Agent in the Treatment or Prevention of an Inflammation-Associated Disorder in the Gastrointestinal Tract of a Mammal |
CN105944101A (zh) * | 2016-04-22 | 2016-09-21 | 刘天军 | 碱性氨基酸修饰氨基四苯基卟啉化合物的新用途 |
CN106188114A (zh) * | 2016-07-13 | 2016-12-07 | 红河学院 | 氟硼取代竹红菌素衍生物的制备及其应用 |
US20170202966A1 (en) * | 2014-06-02 | 2017-07-20 | University Of Exeter | Combinations of a photosensitizer with a hydrogen sulfide donor, thioredoxin inhibitor or nitroxide for use in photodynamic therapy |
CN110960670A (zh) * | 2019-12-11 | 2020-04-07 | 中国药科大学 | 一种藻蓝蛋白肽在制备抗肺纤维化药物中的应用 |
-
2021
- 2021-09-09 CN CN202111058171.6A patent/CN113633771B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5913884A (en) * | 1996-09-19 | 1999-06-22 | The General Hospital Corporation | Inhibition of fibrosis by photodynamic therapy |
US20100087534A1 (en) * | 2005-07-05 | 2010-04-08 | Maria-Anna Ortner | Use of a Photosensitizing Agent in the Treatment or Prevention of an Inflammation-Associated Disorder in the Gastrointestinal Tract of a Mammal |
US20170202966A1 (en) * | 2014-06-02 | 2017-07-20 | University Of Exeter | Combinations of a photosensitizer with a hydrogen sulfide donor, thioredoxin inhibitor or nitroxide for use in photodynamic therapy |
CN105944101A (zh) * | 2016-04-22 | 2016-09-21 | 刘天军 | 碱性氨基酸修饰氨基四苯基卟啉化合物的新用途 |
CN106188114A (zh) * | 2016-07-13 | 2016-12-07 | 红河学院 | 氟硼取代竹红菌素衍生物的制备及其应用 |
CN110960670A (zh) * | 2019-12-11 | 2020-04-07 | 中国药科大学 | 一种藻蓝蛋白肽在制备抗肺纤维化药物中的应用 |
Non-Patent Citations (2)
Title |
---|
SHUAI MENG ET AL: "Synthesis, characterization andin vitrophotodynamic antimicrobialactivity of basic amino acideporphyrin conjugates", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》, 18 December 2014 (2014-12-18), pages 35 - 48 * |
蔡宏等: "瘢痕成纤维细胞对血卟啉单甲醚的吸收特性及其光动 力效应", 《中国激光医学杂志》, vol. 20, 31 October 2011 (2011-10-31), pages 273 - 278 * |
Also Published As
Publication number | Publication date |
---|---|
CN113633771B (zh) | 2024-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106580987B (zh) | 二氢巴马汀抗溃疡性结肠炎的用途 | |
BRPI0712101A2 (pt) | ácido beta-fenil-alfa-hidróxi propanóico substituìdo, método de sìntese e uso do mesmo | |
CN112979528B (zh) | 一种替加色罗水溶性有机酸盐及其制备方法与应用 | |
CA3149590A1 (en) | Fused polypeptide and use thereof | |
Ma et al. | Robust drug bioavailability and safety for rheumatoid arthritis therapy using D-amino acids-based supramolecular hydrogels | |
CN109912693B (zh) | Rgds修饰的七环醛,其合成,抗栓活性和应用 | |
WO2008003245A1 (fr) | Utilisation d'acide rosmarinique pour produire des médicaments destinés à traiter ou à prévenir des maladies hépatiques et rénales | |
CN113633771B (zh) | 氨基酸修饰氨基四苯基卟啉化合物预防治疗纤维化的用途 | |
CN109796429B (zh) | 穿心莲内酯十氢萘结构修饰衍生物系列iii及其制备方法和用途 | |
CN109912694B (zh) | Rgdf修饰的七环醛,其合成,抗栓活性和应用 | |
CN114835897B (zh) | 一种具有pH敏感性以及主动靶向性功能材料及其制备方法和应用 | |
WO2014169697A1 (zh) | 长春碱类衍生物及其制备方法和应用 | |
CN115028681A (zh) | 一种降解亲环素a的嵌合体化合物及其制备方法与应用 | |
CN111205299B (zh) | 一种stat3抑制剂及其应用 | |
CN109912695B (zh) | Rgdv修饰的七环醛,其合成,抗栓活性和应用 | |
CN113185582A (zh) | 一种环五肽Galaxamide及其制备方法与其在制备抗肿瘤药物中的应用 | |
TWI669121B (zh) | Compound for the treatment of cancer | |
CN111450101A (zh) | 一种咪唑吡啶衍生物在药物制备中的应用 | |
US20220251093A1 (en) | Potassium salt crystal form b of phosphodiesterase type 5 inhibitor, and preparation method and use therefor | |
WO2016029669A9 (zh) | 光己醚化合物及其药物组合物和用途 | |
CN117106007B (zh) | 裂环羽扇豆烷衍生物及其在制备多靶点肿瘤血管生成和侵袭转移抑制剂中的应用 | |
CN113234013B (zh) | 一种抑制胶原合成和沉积的化合物及其应用 | |
CN113620873B (zh) | 含锌结合基以及喹啉骨架的化合物的制备方法和用途 | |
RU2404783C1 (ru) | Антиангиогенное лекарственное средство и способ его получения | |
CN115944711A (zh) | 四肽在制备用于黏膜损伤或皮肤损伤修复的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220615 Address after: 300385 6-727, floor 6, block C, Saida emerging industrial park, Xiqing Economic and Technological Development Zone, Xiqing District, Tianjin Applicant after: Tianjin hairunjiahe innovative pharmaceutical research Co.,Ltd. Address before: 300192, 236 Bai Causeway Road, Tianjin, Nankai District Applicant before: CHINESE ACADEMY OF MEDICAL SCIENCES INSTITUTE OF BIOMEDICAL ENGINEERING |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |